Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment

References

• Prelevic GM, Wurzburger MI, Balint-Peric L., et al. Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990; 363: 900–3
   Google Scholar
• Shoup D., Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983; 147: 588–92
   Google Scholar
• Barbieri RI, Smith S., Ryan KZ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50: 197–212
   PubMed Web of Science ®Google Scholar
• Nestler JE, Clore JN, Blachard WG. The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. Am J Obstet Gynecol 1989; 161: 1095–7
   PubMed Web of Science ®Google Scholar
• Dunaif A., Segal KR, Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–74
   PubMed Web of Science ®Google Scholar
• Laatikainen T., Anttila L., Suikkari AM, et al. Effect of naloxone on plasma insulin, insulin-like growth factor-1 and its binding protein-1 in patients with polycystic ovarian disease. Fertil Steril 1990; 54: 434–7
   PubMedGoogle Scholar
• Kazer RR, Unterman TG, Glick RP. An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 71: 958–62
   Google Scholar
• Lanzone A., Fulghesu AM, Pappalardo S., et al. Growth hormone and somatomedin-C secretion in patients with polycystic ovarian disease: their relationships with hyperinsulinism and hyperandrogenism. Gynecol Obstet Invest 1990; 29: 149–53
   PubMedGoogle Scholar
• Suikkari AM, Ruutiaineri K., Erkkola R., et al. Low levels of low molecular weight insulin-like growth factor binding protein in patients with polycystic ovarian disease. Hum Reprod 1989; 4: 136–9
   PubMed Web of Science ®Google Scholar
• Marbach P., Briner U., Lemaire M., et al. From somatostatin to sandostatin. Pharmacodynamics and pharmacokinetics. Metabolism 1992; 41: 7–9
   PubMed Web of Science ®Google Scholar
• Bauer KW, Briner V., Doepfner W., et al. SMS 201-295: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMed Web of Science ®Google Scholar
• Morris RS, Carmina E., Vijod MA, et al. Alterations in the sensitivity of serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertil Steril 1995; 63: 742–6
   Google Scholar
• WHO Scientific Group Report. Agents stimulating gonadal function in the human. World Health Organization. 1973, Technical Report Series
   Google Scholar
• Pless J. From somatostatin to sandostatin: history and chemistry. Metabolism 1992; 41: 5–6
   Google Scholar
• Pawelczyk LA, Duleba AJ, Moon YS, et al. Sandostatin has no direct effect on ovarian steroidogenesis in vitro. Hum Reprod 1993; 8: 364–8
   Google Scholar
• Pekonen F., Laatikainen T., Buyalos R., et al. Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease. Fertil Steril 1989; 51: 972–5
   PubMedGoogle Scholar
• Cara JF, Rosenfield RL. Insulin-like growth factor-1 and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal interstitial cells. Endocrinology 1988; 123: 733–9
   PubMed Web of Science ®Google Scholar
• Poretsky L., Grigorescu F., Siebel M., et al. Distribution and characterization of insulin and insulin-like growth factor. I Receptors in normal human ovary. J Clin Endocrinol Metab 1985; 61: 728–31
   PubMed Web of Science ®Google Scholar
• Hatchinson LA, Findlay JK, Herington AC. Growth hormone and insulin-like growth factor-I accelerate PMSG-induced differentiation of granulosa cells. Mol Cell Endocrinol 1988; 55: 61–9
   Google Scholar
• Erikson GF, Garzo VG, Magoffin DA. Insulin-like growth factor-I regulates aromatase activity in human granulosaluteal cells. J Clin Endocrinol Metabol 1989; 69: 716–24
   Google Scholar
• Piaditis GP, Hatziloanidis AH, Trovas GP, et al. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome. Clin Endocrinol Oxf 1996; 45: 595–604
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Lanzone A., Andreani CL, et al. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 1995; 64: 703–8
   Google Scholar
• Prelevic GM, Ginsburg J., Maletic, et al. The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum Reprod 1995; 10: 28–32
   PubMed Web of Science ®Google Scholar